Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROpel: Olaparib Plus Abiraterone in First-line mCRPC
NCT03732820Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing olaparib plus abiraterone with placebo plus abiraterone (2 arms). Primary endpoint: Radiological Progression Free Survival. Started Oct 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03732820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732820.